Interplay between autophagy and apoptosis in TrkA-induced cell death. 2009

Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
Department of Biochemistry and MRCND and Institute of Health Sciences, Gyeongsang National University School of Medicine, Jinju, Republic of Korea.

Autophagy is a self-eating process to eradicate damaged proteins or organelles in cells. This process begins with formation of a double-membrane structure, called an autophagosome, which can sequester soluble proteins and organelles eventually degraded by lysosomal proteases after fusion with the lysosome. Autophagy was initially identified as a cell survival mechanism under stress conditions such as nutrient deprivation. More recently, it is also considered as type-II programmed cell death. In our recent report, we observed that overexpression of TrkA caused massive cell death via both apoptosis and autophagy. Overexpression of TrkA abated catalase activity and subsequently resulted in the production of a large amount of reactive oxygen species in cells. These consequences led to autophagic cell death. The autophagic cell death in TrkA-overexpressing cells was validated by GFP-LC3 dot formation, production of autophagosomes or acidic vacuoles, LC3 lipidation, and depletion of autopahgy-related genes. In addition, we also observed some evidence for apoptosis in TrkA-expressing cells. Many cells expressing TrkA exhibited annexin V-positive staining, activation of caspase-7 and BAX. Moreover, TrkA activated the JNK pathway, leading to phosphorylation of H2AX. In this report, we suggest that two cell death mechanisms occur simultaneously and interlink with each other. The JNK-calpain pathway might be a central process to mediate the two processes in TrkA-overexpressing cells, although further study still remains to prove the interplay between autophagy and apoptosis.

UI MeSH Term Description Entries
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D002154 Calpain Cysteine proteinase found in many tissues. Hydrolyzes a variety of endogenous proteins including NEUROPEPTIDES; CYTOSKELETAL PROTEINS; proteins from SMOOTH MUSCLE; CARDIAC MUSCLE; liver; platelets; and erythrocytes. Two subclasses having high and low calcium sensitivity are known. Removes Z-discs and M-lines from myofibrils. Activates phosphorylase kinase and cyclic nucleotide-independent protein kinase. This enzyme was formerly listed as EC 3.4.22.4. Calcium-Activated Neutral Protease,Calcium-Dependent Neutral Proteinase,Ca2+-Activated Protease,Calcium-Activated Neutral Proteinase,Calcium-Activated Protease,Calcium-Dependent Neutral Protease,Calpain I,Calpain II,Desminase,Ca2+ Activated Protease,Calcium Activated Neutral Protease,Calcium Activated Neutral Proteinase,Calcium Activated Protease,Calcium Dependent Neutral Protease,Calcium Dependent Neutral Proteinase,Neutral Protease, Calcium-Activated,Neutral Protease, Calcium-Dependent,Neutral Proteinase, Calcium-Activated,Neutral Proteinase, Calcium-Dependent,Protease, Ca2+-Activated,Protease, Calcium-Activated,Protease, Calcium-Activated Neutral,Protease, Calcium-Dependent Neutral,Proteinase, Calcium-Activated Neutral,Proteinase, Calcium-Dependent Neutral
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001343 Autophagy The segregation and degradation of various cytoplasmic constituents via engulfment by MULTIVESICULAR BODIES; VACUOLES; or AUTOPHAGOSOMES and their digestion by LYSOSOMES. It plays an important role in BIOLOGICAL METAMORPHOSIS and in the removal of bone by OSTEOCLASTS. Defective autophagy is associated with various diseases, including NEURODEGENERATIVE DISEASES and cancer. Autophagocytosis,ER-Phagy,Lipophagy,Nucleophagy,Reticulophagy,Ribophagy,Autophagy, Cellular,Cellular Autophagy,ER Phagy
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D050998 bcl-2 Homologous Antagonist-Killer Protein A multi-domain mitochondrial membrane protein and member of the bcl-2 Protein family. Bak protein interacts with TUMOR SUPPRESSOR PROTEIN P53 and promotes APOPTOSIS. Bak Protein,N-Bak Protein,bcl2 Homologous Antagonist-Killer Protein,bcl 2 Homologous Antagonist Killer Protein,bcl2 Homologous Antagonist Killer Protein
D051028 bcl-2-Associated X Protein A member of the Bcl-2 protein family and homologous partner of C-BCL-2 PROTO-ONCOGENE PROTEIN. It regulates the release of CYTOCHROME C and APOPTOSIS INDUCING FACTOR from the MITOCHONDRIA. Several isoforms of BCL2-associated X protein occur due to ALTERNATIVE SPLICING of the mRNA for this protein. Bax Protein,Bax-alpha Protein,Bax-omega Protein,Bax-sigma Protein,Bax Apoptosis Regulator Protein,Bax-beta Protein,Bax-delta Protein,bcl2-Associated X Protein,bcl2-Associated X Protein Isoform alpha,bcl2-Associated X Protein Isoform beta,bcl2-Associated X Protein Isoform delta,bcl2-Associated X Protein Isoform omega,bcl2-Associated X Protein Isoform sigma,Bax alpha Protein,Bax beta Protein,Bax delta Protein,Bax omega Protein,Bax sigma Protein,Protein, bcl-2-Associated X,X Protein, bcl-2-Associated,bcl 2 Associated X Protein,bcl2 Associated X Protein,bcl2 Associated X Protein Isoform alpha,bcl2 Associated X Protein Isoform beta,bcl2 Associated X Protein Isoform delta,bcl2 Associated X Protein Isoform omega,bcl2 Associated X Protein Isoform sigma
D020917 Receptor, trkA A protein-tyrosine kinase receptor that is specific for NERVE GROWTH FACTOR; NEUROTROPHIN 3; neurotrophin 4, neurotrophin 5. It plays a crucial role in pain sensation and thermoregulation in humans. Gene mutations that cause loss of receptor function are associated with CONGENITAL INSENSITIVITY TO PAIN WITH ANHIDROSIS, while gene rearrangements that activate the protein-tyrosine kinase function are associated with tumorigenesis. NTRK1 Receptor,Proto-Oncogene Protein trk,Receptor, Neurotrophic Tyrosine Kinase Type 1,gp140(c-TRK),trk Proto-Oncogene Protein,trkA Receptor,Neurotrophic Tyrosine Kinase Receptor Type 1,Proto-Oncogene Products c-trk,c-trk Protein,gp140 c-trk,p140-trkA,trk1 Transforming Tryrosine Kinase,Proto Oncogene Products c trk,Proto Oncogene Protein trk,Proto-Oncogene Protein, trk,Receptor, NTRK1,c trk Protein,c-trk, Proto-Oncogene Products,c-trk, gp140,gp140 c trk,p140 trkA,trk Proto Oncogene Protein,trk, Proto-Oncogene Protein

Related Publications

Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
March 2014, Biochemical pharmacology,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
January 2022, The Biochemical journal,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
September 2017, Oncotarget,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
August 2013, BMB reports,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
January 2015, Theranostics,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
January 2013, PLoS pathogens,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
January 2010, The FEBS journal,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
January 2024, Cancer letters,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
June 2014, Journal of biochemical and pharmacological research,
Shorafidinkhuja Dadakhujaev, and Eun Joo Jung, and Hae Sook Noh, and Young-Sool Hah, and Chang Jae Kim, and Deok Ryong Kim
June 2016, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine,
Copied contents to your clipboard!